271 related articles for article (PubMed ID: 18309700)
1. Interstitial lung disease in systemic sclerosis.
Renzoni EA
Monaldi Arch Chest Dis; 2007 Dec; 67(4):217-28. PubMed ID: 18309700
[TBL] [Abstract][Full Text] [Related]
2. Interstitial lung disease in systemic sclerosis.
Bussone G; Mouthon L
Autoimmun Rev; 2011 Mar; 10(5):248-55. PubMed ID: 20863911
[TBL] [Abstract][Full Text] [Related]
3. Systemic sclerosis-associated interstitial lung disease.
Perelas A; Silver RM; Arrossi AV; Highland KB
Lancet Respir Med; 2020 Mar; 8(3):304-320. PubMed ID: 32113575
[TBL] [Abstract][Full Text] [Related]
4. Interstitial lung disease in scleroderma.
Schoenfeld SR; Castelino FV
Rheum Dis Clin North Am; 2015 May; 41(2):237-48. PubMed ID: 25836640
[TBL] [Abstract][Full Text] [Related]
5. Mycophenolate mofetil as a therapeutic agent for interstitial lung diseases in systemic sclerosis.
Ueda T; Sakagami T; Kikuchi T; Takada T
Respir Investig; 2018 Jan; 56(1):14-20. PubMed ID: 29325675
[TBL] [Abstract][Full Text] [Related]
6. Where are we going in the management of interstitial lung disease in patients with systemic sclerosis?
Iudici M; Moroncini G; Cipriani P; Giacomelli R; Gabrielli A; Valentini G
Autoimmun Rev; 2015 Jul; 14(7):575-8. PubMed ID: 25709096
[TBL] [Abstract][Full Text] [Related]
7. Good outcome of interstitial lung disease in patients with scleroderma associated to anti-PM/Scl antibody.
Guillen-Del Castillo A; Pilar Simeón-Aznar C; Fonollosa-Pla V; Alonso-Vila S; Reverte-Vinaixa MM; Muñoz X; Pallisa E; Selva-O'allaghan A; Fernández-Codina A; Vilardell-Tarrés M
Semin Arthritis Rheum; 2014 Dec; 44(3):331-7. PubMed ID: 25110305
[TBL] [Abstract][Full Text] [Related]
8. Interstitial lung disease in systemic sclerosis.
Wells AU; Margaritopoulos GA; Antoniou KM; Denton C
Semin Respir Crit Care Med; 2014 Apr; 35(2):213-21. PubMed ID: 24668536
[TBL] [Abstract][Full Text] [Related]
9. Centrilobular fibrosis: an underrecognized pattern in systemic sclerosis.
de Souza RB; Borges CT; Capelozzi VL; Parra ER; Jatene FB; Kavakama J; Kairalla RA; Bonfá E
Respiration; 2009; 77(4):389-97. PubMed ID: 18799868
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in the diagnosis and treatment of interstitial lung disease in systemic sclerosis (scleroderma): a review.
Tan A; Denton CP; Mikhailidis DP; Seifalian AM
Clin Exp Rheumatol; 2011; 29(2 Suppl 65):S66-74. PubMed ID: 21586221
[TBL] [Abstract][Full Text] [Related]
11. [Interstitial lung disease (ILD) in systemic sclerosis (SSc)].
Novak S
Reumatizam; 2010; 57(2):105-8. PubMed ID: 21875013
[TBL] [Abstract][Full Text] [Related]
12. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group.
Jordan S; Distler JH; Maurer B; Huscher D; van Laar JM; Allanore Y; Distler O;
Ann Rheum Dis; 2015 Jun; 74(6):1188-94. PubMed ID: 24442885
[TBL] [Abstract][Full Text] [Related]
13. Association of gastroesophageal factors and worsening of forced vital capacity in systemic sclerosis.
Zhang XJ; Bonner A; Hudson M; ; Baron M; Pope J
J Rheumatol; 2013 Jun; 40(6):850-8. PubMed ID: 23547215
[TBL] [Abstract][Full Text] [Related]
14. Investigation of prognostic factors for skin sclerosis and lung function in Japanese patients with early systemic sclerosis: a multicentre prospective observational study.
Hasegawa M; Asano Y; Endo H; Fujimoto M; Goto D; Ihn H; Inoue K; Ishikawa O; Kawaguchi Y; Kuwana M; Muro Y; Ogawa F; Sasaki T; Takahashi H; Tanaka S; Takehara K; Sato S
Rheumatology (Oxford); 2012 Jan; 51(1):129-33. PubMed ID: 22072085
[TBL] [Abstract][Full Text] [Related]
15. Current and future perspectives on management of systemic sclerosis-associated interstitial lung disease.
Distler O; Volkmann ER; Hoffmann-Vold AM; Maher TM
Expert Rev Clin Immunol; 2019 Oct; 15(10):1009-1017. PubMed ID: 31566449
[No Abstract] [Full Text] [Related]
16. Interstitial lung disease points to consider for clinical trials in systemic sclerosis.
Khanna D; Seibold J; Goldin J; Tashkin DP; Furst DE; Wells A
Rheumatology (Oxford); 2017 Sep; 56(suppl_5):v27-v32. PubMed ID: 28992174
[TBL] [Abstract][Full Text] [Related]
17. Current Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease.
Bes C; Çetinkaya E
Tuberk Toraks; 2022 Mar; 70(1):85-92. PubMed ID: 35362308
[TBL] [Abstract][Full Text] [Related]
18. Procollagen Type I and III Aminoterminal Propeptide Levels and Severity of Interstitial Lung Disease in Mexican Women With Progressive Systemic Sclerosis.
Gonzalez-Lopez L; Rocha-Muñoz AD; Olivas-Flores EM; Garcia-Gonzalez A; Peguero-Gómez AR; Flores-Navarro J; Villa-Manzano AI; Zavaleta-Muñiz SA; Salazar-Paramo M; Mejía M; Juárez-Contreras P; Vazquez-Del Mercado M; Cardona-Muñoz EG; Trujillo-Hernández B; Nava-Zavala AH; Gamez-Nava JI
Arch Bronconeumol; 2015 Sep; 51(9):440-8. PubMed ID: 25301411
[TBL] [Abstract][Full Text] [Related]
19. Low-dose pulse cyclophosphamide in interstitial lung disease associated with systemic sclerosis (SSc-ILD): efficacy of maintenance immunosuppression in responders and non-responders.
Iudici M; Cuomo G; Vettori S; Bocchino M; Sanduzzi Zamparelli A; Cappabianca S; Valentini G
Semin Arthritis Rheum; 2015 Feb; 44(4):437-44. PubMed ID: 25282395
[TBL] [Abstract][Full Text] [Related]
20. [Use of pulmonary function tests and biomarkers studies to diagnose and follow-up interstitial lung disease in systemic sclerosis].
Hua-Huy T; Rivière S; Tiev KP; Dinh-Xuan AT
Rev Pneumol Clin; 2014 Dec; 70(6):335-42. PubMed ID: 25457218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
